Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM701 as Maintenance Therapy in Relapsed Platinum Sensitive Ovarian Cancer
NCT06888921Phase 2Active, not recruiting
- Sponsor
- Compugen Ltd.
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of COM701 in ovarian cancer (2 arms), sponsored by Compugen Ltd. Primary endpoint: Progression-Free Survival up to 2 years. Started Jul 2025; status: active, not recruiting.
02
Drugs
COM701
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06888921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888921.